CClinicalTrials.gg
RecruitingNCT05921838Updated Jun 27, 2023

The Role of Circ0014614 in the Formation and Development of ET

An observational study in Primary Thrombocytosis, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-06-27.

Sponsored by Nanfang Hospital, Southern Medical University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 9 months later.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
120
Ages
18 Years to 64 Years
Sex
All
01

Study summary

Research on the Role of Circ0014614 in the Formation and Development of ET

Read the detailed description

In recent years, tumor niche involved in the development of myeloproliferative disease(MPN), which is remodelled by stem progenitor cells driving gene mutation, has attracted attention, but the reason and mechanism of remodelling microenvironment by mutated hematopoietic stem cells( HSCs) are poorly understood. Our previous studies have shown that there is an obstacle in the transport of extracellular vesicles circ0014614 from MEPs in ET patients, which is enriched in the cytoplasm of megakaryocyte-erythroid progenitor(MEPs), causing abnormal proliferation and reduced apoptosis of MEPs. The amplified MEPs affect the ossification of Mesenchymal stem cells(MCSs). Based on this, we propose a hypothesis that circ0014614 may cause abnormal amplification of MEPs, reshape niche, induce ossification of MCSs, and abnormal amplification of osteoblasts(OBCs) through a certain pathway, promoting the formation and development of ET. This study will expand the collection of bone marrow samples from Essential thrombocytosis(ET) patients, detect the differences in circ0014614 levels in peripheral blood and bone marrow before and after treatment, and predict its downstream microRNA and mRNA through bioinformatics analysis to speculate its role in the occurrence and development of the disease. In recent years, tumor niche involved in the development of MPN, which is remodelled by stem progenitor cells driving gene mutation, has attracted attention, but the reason and mechanism of remodelling microenvironment by mutated HSCs are poorly understood. Our previous research has shown that there is an obstacle in the transport of extracellular vesicles circ0014614 from MEPs in ET patients, which is enriched in the cytoplasm of MEPs, causing abnormal proliferation and reduced apoptosis of MEPs. The amplified MEPs affect the ossification of MCSs. Based on this, we propose a hypothesis that circ0014614 may cause abnormal amplification of MEPs, reshape niche, induce ossification of MCSs, and abnormal amplification of OBCs through a certain pathway, promoting the formation and development of ET. This study will expand the collection of bone marrow samples from ET patients, detect the differences in circ0014614 levels in peripheral blood and bone marrow before and after treatment, and predict its downstream microRNA and mRNA through bioinformatics analysis to speculate its role in the occurrence and development of the disease.

02

Conditions studied

  • Primary Thrombocytosis
03

In context

Thrombocytosis

157 studies on the registry are indexed under Thrombocytosis; 21 are open to participants now.

This study's planned enrollment of 120 is below the median of 200 across 33 observational studies indexed under Thrombocytosis.

Browse Thrombocytosis studies →

Lead sponsor

Nanfang Hospital, Southern Medical University is the lead sponsor of 480 studies on the registry; 212 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

ET patients treated with interferon

Inclusion criteria

  1. According to the classification and diagnostic criteria of hematological myeloid tumors by WHO 2016, patients diagnosed as ET are standardized
  2. Voluntary signing of informed consent form
  3. Age ≥ 18 years old, regardless of gender
  4. No pregnancy plan during treatment

Exclusion criteria

Exclusion Criteria:

1.The researcher judged that it was not suitable to participate in this study

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • ET patients

    patients suffer from primary thrombocytosis

  • healthy doner

    Healthy individuals without blood system diseases

06

What researchers measure

Primary outcomes

  1. Circ0014614 copies in ET patients treated with interferon for 8 months

    Circ0014614 copies in ET patients treated with interferon for 8 months

    Time frame: 8months

07

Study locations

1 of 1 sites recruiting
  • Department of Hematology,Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong 510515, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05921838
Lead sponsor
Nanfang Hospital, Southern Medical University
Responsible party
Sponsor
First posted
Jun 27, 2023
Start date
Jan 1, 2021
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Jun 27, 2023

Study contacts

Dan Xu
Contact
522111156@qq.com
+86-20-61641615
Xiaofan Chen
Contact
522111156@qq.com
+86-20-61641615
Dan Xu
principal investigator · Nanfang Hospital, Southern Medical University
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion